Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Gastric Adenocarcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Adalimumab 13Methotrexate 11Etanercept 10Rituximab 5Abatacept 5tocilizumab 4olokizumab 4tofacitinib 3golimumab 3Infliximab 3Tumor Necrosis Factor Inhibitors 2Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2Certolizumab Pegol 2Antirheumatic Agents 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Arthritis, Rheumatoid × andecaliximab × Clear all
NCT02862574 2018-06-27

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Gilead Sciences

Phase 2 Terminated
15 enrolled 11 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡